ML20044C103

Provides Key Schedule Dates for Completion of All Info Required for Staff to Complete Review of Abwr,As follow-up to 930225 Meeting.Licensee Will Submit Final SSAR by 930731

ML20044C103
Person / Time
Site:	05200001
Issue date:	03/08/1993
From:	Recasha Mitchell GENERAL ELECTRIC CO.
To:	Crutchfield D Office of Nuclear Reactor Regulation
References
MFN-027-93, MFN-27-93, NUDOCS 9303170239
Download: ML20044C103 (2)

Text

+

gj

=-

q j

q q/

y GENuclearEnergy Genera!Dnctre Corr >pany 1?5 Curtner Avemw. San Jese. CA 95125 March 8,1993 Docket No. 52-001-MFN No. 027-93 Mr. Dennis M. Crutchfield Associate Director, Advanced Reactors and License Renewal Office of Nuclear Reactor Regulation

Subject:

Kev Schedule Dates for ABWR Review

Dear Mr. Crutchfield:

~

As follow-up to the meeting which took place on February 25,1993, this letter provides

~

GE's key schedule dates for completion of all information required for the Staff to complete its reviews of the ABWR.' Of course, this objective cannot be achieved '

without quality and technically complete.SSAR and ITAAC submittals on the part of GE, and timely review on the part of the Staff.

As previously advised, GE will submit by July 31,1993 a final SSAR, verified and reformatted, which will resolve all DFSER outstanding items; a non-proprietary Tier 1 design description; and a complementary integrated set ofITAAC. As prescribed by 10 CFR 52A5(d), this submittal will comply with the filing requirements of 10 CFR 50.30(b).

To facilitate timely Staff review, GE further commits to continue its submittals of marked-up versions of SSAR sections, as developed, such that the Staff will have been provided all substantive modifications well in advance of theJuly. submittal. The marked-up SSAR sections will reflect GE's understanding of what it takes to close.each of the design-related DFSER outstanding items. Following ~ confirmation by the Staff that the markup does in fact provide the information to close the item (s), GE will submit amendments to the SSAR to formally document closure of each DFSER item.

The last of the SSAR amendments, closing the last of the design-related DFSER '

outstanding items, will be provided by May 28,1993.

To further facilitate timely Staff review, GE also intends to make sequential submittals of the ABWR ITAAC as they become available, in advance of theJuly submittal. It is anticipated these sequential ITAAC submittals will receive expedited Staff review.

This is essential to avoid a lengthy post-July Tier 1/ITAAC review. With this early Staff review, theJuly submittal can reflect resolution of all Tier 1 and ITAAC outstanding items as well as'the design-related outstanding items in the DFSER.-

The SSAR verification process is currently underway and, when completed, will provide assurance that (1) the final SSAR properly reflects its design documentation,-

3 17Gon ARN93;)

9303170239 930308

$go PDR ADDcK 0520 0 1-A

i

~

Mr. Dennis M. Crutchfield March 8,1993 Page 2 of 2 (2) the final SSAR is technically accurate and consistent within itself, and (3) the Tier 1 material and the final SSAR are consistent. To better facilitate verification of the SSAR, a reformatted SSAR (i.e., final SSAR) is being developed using a new format similar to the format of the SBWR SSAR. GE understands that NRC plans to perform a verification of the final SSAR. No technical issues should result from this verification.

We note the acknowledgement in SECV93-041 that the NRC Staff can legally issue an FDA witimut approval of the Design Control Document (DCD) - approval of the DCD being linked to the ensuing step ofinitiating certification rulemaking. Since both tiers ofinformation that constitute the DCD will have been reviewed and approved by the NRC as part ofits FDA determinations, there is no reason why the formal creation of a DCD for inclusi,n in a notice of proposed rulemaking need be accomplished prior to FDA issuance. Requiring such a step would result in a needless process delay. NRC verification of DCD content - projected in SECY-9%41 - can be done with full effectiveness after issuance of the FDA. Accordingly, we strongly recommend that an FDA be issued as soon as the FSER is issued.

We appreciate the Staff review commitment and the supporting resources reflected in SECV9%41 and assure the NRC that GE fully intends to fulfill its reciprocal submittal responsibilities.

Sincerely, Q.C A dAk R. C. Mitchell, Acting Manager Safety & Licensing MC444, (408) 92%948 ARPl/93j